Proton Pump Inhibitor Dosing in Chronic Kidney Disease

General PPI Considerations in CKD

PPIs are commonly prescribed to CKD patients, particularly for gastroprotection when using antiplatelet therapy, with the European Society of Cardiology recommending their use for patients at high risk of gastrointestinal bleeding 1, 2
PPIs are recommended for patients receiving aspirin monotherapy, dual antiplatelet therapy (DAPT), or oral anticoagulant monotherapy who are at high risk of gastrointestinal bleeding, as suggested by the European Heart Journal 2

The American Journal of Kidney Diseases recommends the following standard dosing for PPIs in CKD patients: Omeprazole 20-40 mg daily, Lansoprazole 15-30 mg daily, Pantoprazole 20-40 mg daily, Esomeprazole 20-40 mg daily, and Rabeprazole 20 mg daily 3
Unlike many medications, PPIs do not require dose adjustment based on CKD stage or glomerular filtration rate (GFR), according to the American Journal of Kidney Diseases 3

For CKD patients receiving antiplatelet therapy (particularly aspirin), PPI co-administration is recommended to reduce gastrointestinal bleeding risk, as suggested by the European Heart Journal 1, 2
In patients with both CKD and cardiovascular disease requiring antiplatelet therapy, PPI use is particularly important for gastroprotection, according to the European Heart Journal 2

Monitor for potential drug interactions, particularly with medications that have narrow therapeutic windows, as recommended by the American Journal of Kidney Diseases 3